Beyond the hype. Beyond the stigma.
Scientific interest in psychedelic compounds has returned after decades at the margins of mainstream medicine.
The questions now extend far beyond whether these substances "work."
How strong is the evidence? For whom might benefits occur—and what are the risks? What role do context and expectation play? How should traditional and Indigenous knowledge interact with modern medicine? What happens when psychedelics become commercial products? And how should society approach extraordinary experiences that can be simultaneously neurological, psychological, cultural and deeply personal?
The Brazen Word follows the research, regulation, culture and controversies surrounding psychedelics without assuming where the evidence will lead.
Explore Topics
Eating disorders can involve deeply entrenched patterns of body image, self-perception, emotion and behavior. Early studies are asking whether psychedelic-assisted approaches might help loosen some of those patterns. The possibility is intriguing—but the evidence remains preliminary.
SSRIs and other psychiatric medications can alter the effects of some psychedelics, while stopping antidepressants carries its own risks. New research is challenging the assumption that patients must always discontinue conventional treatment before psychedelic therapy.
New treatments can expand what is possible in medicine. But innovation means little to patients who cannot afford it, reach it, trust it or find clinicians prepared to provide it. As ketamine, esketamine and psychedelic therapies develop, an old healthcare question is becoming newly urgent: who actually gets access?
IV ketamine is widely regarded as the gold-standard route for off-label racemic ketamine treatment in psychiatry. But ketamine can also be administered intramuscularly, intranasally, orally and sublingually—and esketamine is available as an FDA-approved nasal spray. These approaches are not interchangeable. Route changes the pharmacology, precision, monitoring and potentially the experience itself.
DMT can produce one of the strangest recurring phenomena in psychedelic research: encounters with apparently autonomous beings. Thousands of people describe them as intelligent, communicative and startlingly real. What can science actually tell us about these experiences?
Psychedelic medicine has moved from the scientific margins into serious clinical and regulatory development. But growing interest should not be confused with approval—and the evidence, legality and accessibility vary considerably from one substance to another.
Research in people facing cancer and other life-threatening illnesses suggests psilocybin may reduce anxiety, depression and existential distress. But what exactly is changing—and how strong is the evidence?
Ketamine changed depression research by demonstrating that psychiatric symptoms could sometimes improve within hours. Now researchers are investigating its potential across PTSD, OCD, addiction, eating disorders, sleep—and even neurological disease. Some applications are supported by meaningful human evidence. Others remain almost entirely experimental. Where does the science actually stand?